Tuesday, March 4, 2014

Approved autism drug fails to deliver long term for most

Aripiprazole, one of two autism drugs approved by the U.S. Food and Drug Administration to treat irritability in people with autism, may be no more effective than a placebo in the long run for some children, reports a study published in the January issue of the Journal of Clinical Psychiatry. When taken for eight weeks or less, aripiprazole quiets tantrums, stabilizes rapid mood swings and abates self-injuring behaviors in children with autism. But the benefits of this antipsychotic drug can fall off after several months, according to the new study. Aripiprazole is the second-most-prescribed drug in the U.S. for both children and adults with the disorder.

 Read more here.